{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9WUZFWHO/d4496206-142d-4ebb-9a79-ccb0368f0a48/PDF","dcterms:extent":"426 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-9WUZFWHO/20647363-db2b-414a-88ba-ebf51e7e1f54/TEXT","dcterms:extent":"25 KB"}],"edm:TimeSpan":{"@rdf:about":"1992-2025","edm:begin":{"@xml:lang":"en","#text":"1992"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-9WUZFWHO","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S"},{"@xml:lang":"sl","#text":"Radiology and oncology (Ljubljana)"}],"dcterms:issued":"1998","dc:creator":["Bešlija, Samir","Brecelj, Erik","Cizej, Tomaž-Edvard","Markovič, Aleksandra","Štabuc, Borut"],"dc:format":[{"@xml:lang":"sl","#text":"letnik:32"},{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"str. 407-415"}],"dc:identifier":["ISSN:1318-2099","COBISSID:8142809","URN:URN:NBN:SI:doc-9WUZFWHO"],"dc:language":"en","dc:publisher":[{"@xml:lang":"sl","#text":"Croatian Medical Association - Croatian Society of Radiology"},{"@xml:lang":"sl","#text":"Slovenian Medical Society - Section of Radiology"}],"dc:subject":[{"@xml:lang":"sl","#text":"Clinical trials, phase ii"},{"@xml:lang":"sl","#text":"Colonic neoplasms"},{"@xml:lang":"sl","#text":"črevesje"},{"@xml:lang":"sl","#text":"debelo črevo"},{"@xml:lang":"sl","#text":"Drug therapy"},{"@xml:lang":"sl","#text":"Drug therapy, combination"},{"@xml:lang":"sl","#text":"Fluorouracil"},{"@xml:lang":"sl","#text":"Interferon alfa-2a"},{"@xml:lang":"sl","#text":"Leucovorin"},{"@xml:lang":"sl","#text":"rak (medicina)"},{"@xml:lang":"sl","#text":"Survival analysis"},{"@xml:lang":"sl","#text":"Therapeutic use"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1992-2025"},"dc:title":{"@xml:lang":"sl","#text":"Phase II study of fluorouracil, leucovorin and interferon alpha-2a in patients with advanced colon cancer|"},"dc:description":[{"@xml:lang":"sl","#text":"Based on in viro studies that have demonstrated synergy between fluorouracil (5-FU) and leucovorin (LV) as well as between 5-FU and recombinant alpha-2a interferon (IFN) against colon cancer cell lines a phase II study was carried out to evaluate the toxicity and clinical activity of 5-FU modulated with LV and IFN in patients with metastatic colon cancer. Twenty-two chemotherapy naive patients with measurable metastases of colon cancer have been treated with daily doses of 5-FU 600 mg/m2 in 6-hr intravenous infusion, and of LV 20 mg/m2 intravenously and IFN 6 MU subcutaneously, for 5 days every 4 weeks. Median age was 60 years, median PS (ECOG) was 1 (range 0-2). Liver, soft tissue and lung metastases were found in 12, 5 and 8 patients, respectively. Nineteen patients had a single metastatic site, two double, whereas one had more than two metastatic sites. Patients had 2-9 (mean 5) cycles of treatment.Objective response was observed in 7 patients (32%), and stable disease in 7 patients (32%). Overall median survival was 12.5 months, and for responders 14.4 months. Responses were generally short and median time for progression was 5.5 months. The most frequent adverse reactions were flu-like syndrome (50%), nausea/vomiting (36%), diarhoea (13Č), stomatitis (27%) and leucopenia (13%). This regimen of 5-FU with LV and IFN administration does notappear to be superior to previously published shedules of 5-FU with IFN or 5-FU with LV"},{"@xml:lang":"sl","#text":"Predklinične raziskave so pokazale sinergistični protitumorski učinek fluorouracila (5-FU), levkorina (LV) ter 5-FU in ekombinantnega interferona alfa-2a (IFN). V II. fazi klinične raziskave smo želeli pri bolnikih z metastatskim rakom širokega črevesa ugotoviti toksičnost in učinkovitost zdravljenja s 5-FU, LV in IFN. V raziskavo smo vključili 22 bolnikov z merljivimi zasevki metastatskega raka širokega črevesa. 5-FU smo dajali v 6-urni intravenski infuziji v dnevnem odmerku 600 mg/m2, LV intravensko v dnevnem odmerku 20 mg/m2 in IFN podkožno v dnevnem odmerku 6 MIE. U_inkovine smo dajali 5 dni zapored vsake 4 tedne. Srednja starost bolnikov je bila 60 let. Srednje stanje zmogljivosti (ECOG) je bilo ocenjeno z 1 (rang 0-2). Dvanajst bolnikov je imelo zasevke v jetrih, 5 v mehkih tkivih in 8 v pljučih.Zasevke v enem organu je imelo 19 bolnikov, v dveh organih 2 bolnika in v 3 organih eden. Bolniki so imeli 2 in 9 ciklov zdravljenja, v povprečju 5ciklov. Objektivni odgovor na zdravljenje smo ugotovili pri 7 bolnikih (32%),mirovanje bolezni pri 7 bolnikih (32%). Srednje preživetje je bilo 12,5 meseca, pri bolnikih, ki so odgovorili na zdravljenje pa 14,4 meseca. Odgovorina zdravljenje so bili kratkotrajni in so v povprečju trajali 5,5 meseca. Med neželenimi učinki zdravljenja smo gripozni uotovili pri 50%, slabost in bruhanje pri 36%, drisko pri 13%, stomatitis pri 27% in levkopenijopri 13% bolnikov. Kombinirano zdravljenje s 5-FU, LV in IFN glede na rezultate dosedanjih kliničnih raziskav s 5-FU in LV ali 5-FU in IFN ni bolj učinkovit način zdravljenja"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-9WUZFWHO","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-9WUZFWHO"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-9WUZFWHO/d4496206-142d-4ebb-9a79-ccb0368f0a48/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Onkološki inštitut Ljubljana"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-9WUZFWHO/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-9WUZFWHO"}}}}